| __timestamp | MiMedx Group, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12665000 | 14400000 |
| Thursday, January 1, 2015 | 20202000 | 33800000 |
| Friday, January 1, 2016 | 32407000 | 35900000 |
| Sunday, January 1, 2017 | 35219000 | 1254000 |
| Monday, January 1, 2018 | 36386000 | 4889000 |
| Tuesday, January 1, 2019 | 43081000 | 7400000 |
| Wednesday, January 1, 2020 | 39330000 | 10100000 |
| Friday, January 1, 2021 | 43283000 | 14300000 |
| Saturday, January 1, 2022 | 48316000 | 23200000 |
| Sunday, January 1, 2023 | 54634000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Data in motion
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. Over the past decade, Neurocrine Biosciences, Inc. and MiMedx Group, Inc. have demonstrated contrasting trends in their cost of revenue. From 2014 to 2023, MiMedx consistently reported higher costs, peaking at approximately $54.6 million in 2023, a 330% increase from 2014. In contrast, Neurocrine's cost of revenue fluctuated, with a notable dip in 2017, but ultimately rose to about $39.7 million by 2023, marking a 176% increase from 2014.
This divergence highlights MiMedx's steady growth in operational expenses, while Neurocrine's variable costs suggest strategic shifts or operational challenges. Understanding these trends provides valuable insights into each company's operational strategies and market positioning. As the biotech sector evolves, monitoring such financial metrics will be crucial for investors and industry analysts alike.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Viatris Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Analyzing Cost of Revenue: Pharming Group N.V. and MiMedx Group, Inc.
Cost of Revenue Comparison: Cytokinetics, Incorporated vs MiMedx Group, Inc.